11 completed, 4 active not recruiting, 4 recruiting, 3 terminated. 24 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 24 | Completed 11, Active not recruiting 4, Recruiting 4, Terminated 3, Not yet recruiting 1, Withdrawn 1 |
| Phase 1 | 4 | Completed 2, Active not recruiting 1, Recruiting 1 |
Follow Acute Biphenotypic Leukemia: new trials by email Literature Review of Acute Biphenotypic Leukemia trials Research Report on Acute Biphenotypic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Pre-transplant conditioning - Reduced Intensity (RIC) - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Ossium Health, Inc. | 12 | 2024-08-16 | 2026-09-10 |
| Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes Dilanubicel, Cyclophosphamide, Fludarabine - Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 31 | 2022-05-10 | 2026-07-10 |
| Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms Cladribine, Cytarabine, Mitoxantrone - Acute Biphenotypic Leukemia, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | University of Washington | 62 | 2022-02-04 | 2026-04-17 |
| Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Anti-CD123/CD3 Monoclonal Antibody MGD006 - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Withdrawn | City of Hope Medical Center | 2020-10-20 | 2020-12-17 | |
| Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting Azacitidine, Venetoclax - Acute Bilineal Leukemia, Acute Biphenotypic Leukemia | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 100 | 2020-05-05 | 2026-10-05 |
| Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant Total-Body Irradiation, Thiotepa, Fludarabine - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 45 | 2019-08-29 | 2026-09-25 |
| Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation Azacitidine, Enasidenib Mesylate - Acute Bilineal Leukemia, Acute Biphenotypic Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 50 | 2018-09-18 | 2026-09-14 |
| Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma Anti-Thymocyte Globulin, Busulfan, Clofarabine - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 6 | 2017-10-13 | 2023-10-11 |
| Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant Ibrutinib, Laboratory Biomarker Analysis - Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Completed | Andrew Rezvani | 8 | 2017-09-12 | 2023-08-01 |
| Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia Platelet Transfusion - Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 4 | 2017-06-09 | 2019-10-21 |
| Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Cladribine, Cytarabine, Filgrastim - Acute Biphenotypic Leukemia, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | University of Washington | 84 | 2016-12-01 | 2023-07-05 |
| Personalized NK Cell Therapy in CBT Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 100 | 2016-05-19 | 2026-11-02 |
| Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia Azacitidine, Lirilumab - Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Terminated | M.D. Anderson Cancer Center | 36 | 2015-04-20 | 2019-09-24 |
| Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia Azacitidine, Ipilimumab, Venetoclax - Acute Bilineal Leukemia, Acute Biphenotypic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 150 | 2015-04-07 | 2025-06-08 |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 84 | 2015-03-23 | 2026-06-01 |
| Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia Clofarabine, Cytarabine, Dexamethasone - Acute Bilineal Leukemia, Acute Biphenotypic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 16 | 2014-10-27 | 2024-03-22 |
| Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia Cladribine, Cytarabine, Gilteritinib - Acute Biphenotypic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 508 | 2014-05-19 | 2026-05-20 |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children Allogeneic Hematopoietic Stem Cell Transplantation, Fludarabine Phosphate, Laboratory Biomarker Analysis - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 20 | 2014-04-10 | 2024-03-12 |
| Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Cladribine, Cytarabine, Filgrastim - Acute Biphenotypic Leukemia, de Novo Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 199 | 2014-01-23 | 2020-01-10 |
Showing 20 of 24. Sign in to see all of them.
Leukemia, Biphenotypic, Acute (24) · Leukemia, Myeloid, Acute (17) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (13) · Myelodysplastic Syndromes (13) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (12) · Anemia, Refractory, with Excess of Blasts (5) · Hodgkin Disease (5) · Blastic Plasmacytoid Dendritic Cell Neoplasm (4) · Burkitt Lymphoma (4) · Leukemia, Myeloid, Accelerated Phase (4) · Leukemia, Myelomonocytic, Chronic (4) · Blast Crisis (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Leukemia, Myeloid, Chronic-Phase (3) · Lymphoma, Non-Hodgkin (3)
Hemic and Lymphatic Diseases (24) · Immune System Diseases (24) · Immunoproliferative Disorders (24) · Leukemia, Lymphoid (24) · Lymphatic Diseases (24) · Lymphoproliferative Disorders (24) · Neoplasms (24) · Neoplasms by Histologic Type (24) · Leukemia (23) · Hematologic Diseases (22) · Leukemia, Myeloid (21) · Bone Marrow Diseases (19) · Chronic Disease (16) · Disease Attributes (16) · Pathologic Processes (16)
Whole-Body Irradiation (11) · Cyclophosphamide (10) · fludarabine phosphate (8) · Mycophenolic Acid (7) · Cord Blood Stem Cell Transplantation (6) · Thiotepa (6) · Cytarabine (5) · Filgrastim (5) · Tacrolimus (5) · fludarabine (5) · Azacitidine (4) · Cladribine (4) · Granulocyte Colony-Stimulating Factor (4) · venetoclax (4) · Busulfan (3)
Fred Hutchinson Cancer Center (10) · M.D. Anderson Cancer Center (8) · University of Washington (2) · Andrew Rezvani (1) · City of Hope Medical Center (1) · Nohla Therapeutics, Inc. (1) · Ossium Health, Inc. (1)
United States (23)
Filippo Milano (3) · Marie Bleakley (3) · Naval Daver (2) · Amanda Olson (1) · Andrew Rezvani (1) · Ann E. Dahlberg (1) · Anna Halpern (1) · Betul Oran (1) · Courtney DiNardo (1) · David Garcia (1) · Elias Jabbour (1) · Ibrahim Aldoss, MD (1) · Mary-Beth M. Percival (1) · Phuong Vo, MD (1) · Rachel B. Salit (1)
PMID 35007144, PMID 29702001, PMID 32706891, PMID 33049057, PMID 34329576, PMID 34980577, PMID 35078972, PMID 37339483, PMID 38391202, PMID 40193193, PMID 40500616, PMID 40535475
P30CA015704 (6), P01CA018029 (3), P50HL110787 (2), R01HL121568 (2), K23CA154532 (1), P30CA016672 (1), R01CA211044 (1)